The Hill

Lyme disease vaccine 70 percent effective: Pfizer

A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be ...

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

Pfizer (PFE 1.60%) and Moderna (MRNA 1.89%) were both leaders in the coronavirus vaccine market. However, as sales of these ...

Pfizer: I'm Still Expecting A Massive Rebound

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...
InvestorsHub on MSN

Pfizer’s TALZENNA combination shows progress against prostate cancer

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...
BioPharma Dive

Pfizer aims for wider use of PARP drug in prostate cancer with new data

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...